CYP2D6 IMs and PMs have a higher risk of breast cancer recurrence when treated with tamoxifen (Goetz et al., 2018) and an impaired metabolism has been reported during atomoxetine treatment (Brown et al., 2019). This evidence concerns the gene CYP2D6 and breast carcinoma.